Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Strides’ Stelis Wins FDA Approval For Bengalaru Injectables Facility

Paves the Way For The Firm’s Continued Push Into US Market

Executive Summary

Stelis BioPharma’s flagship Indian manufacturing facility has been cleared under an FDA Establishment Inspection Report.

You may also be interested in...



Hyloris Ramps Up Product Expansion With New Idiopathic Rhinitis Spray

Hyloris Pharmaceuticals’ new idiopathic rhinitis treatment sets it on track to achieve its target of around 30 portfolio assets by the end of 2024. 

Biocon And Zentiva Sign Liraglutide Deal For 30 European Countries

Zentiva gains semi-exclusive commercialization rights to Biocon’s liraglutide drug-device combination in 30 countries, following a string of similar deals for the company since its 2018 acquisition.

Teva To Advance Digihaler Data Ecosystem With Rimdi And HealthSnap

Teva’s new partnerships will make patient data from its digital inhalers more accessible to healthcare providers, potentially placing Teva’s asthma platform at the forefront of emerging treatment paradigms.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel